{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004539007,0.0003442777,0.001352743,0.000450106,0.0001482159,0.000006998942,0.0001525407,0.00008869635,0.001033549],"category_scores_gemma":[0.00008779063,0.0002328384,0.00008634811,0.0009057756,0.0003518783,0.0000825902,0.0001764427,0.0002147937,0.000003036932],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001508836,"about_ca_system_score_gemma":0.00007780828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000456813,"about_ca_topic_score_gemma":0.0001147284,"domain_scores_codex":[0.9973565,0.0003710128,0.0008302462,0.0005792908,0.0004474305,0.0004155199],"domain_scores_gemma":[0.9974508,0.001573325,0.0002802827,0.0004528208,0.0001289394,0.0001138535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01799018,0.00173793,0.9229407,0.0002697856,0.001098614,0.00004851326,0.005118588,0.02711391,0.00002821303,0.0008638612,0.00004565844,0.02274411],"study_design_scores_gemma":[0.04101514,0.009886449,0.8957158,0.0007160172,0.002512103,0.0002027103,0.003909707,0.0221569,0.003134487,0.0003659642,0.01945017,0.0009345902],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993197,0.004626224,0.0000557991,0.0005415898,0.00001640179,0.001224775,0.0001988012,0.00001239097,0.0001270827],"genre_scores_gemma":[0.9976799,0.0008520269,0.0004474908,0.0004257932,0.00001173931,0.00031163,0.0001551063,0.00002755356,0.00008879689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02722489,"threshold_uncertainty_score":0.9998797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01325738480847344,"score_gpt":0.2773913357063457,"score_spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}